UroGen Pharma (URGN) Operating Leases (2019 - 2026)
UroGen Pharma's (URGN) quarterly Operating Leases came in at $5.6 million in Q1 2026, up 98.77% YoY from $2.8 million in Q1 2025, and down 7.76% on a QoQ basis from $6.1 million in Q4 2025.
UroGen Pharma (URGN) Operating Leases (2019 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 8 years of Operating Leases data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Operating Leases rose 98.77% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 98.77% YoY) and the FY2025 annual result came in at $6.1 million, up 270.36% from the prior year.
- Operating Leases slipped to $5.6 million in Q1 2026, from $6.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $6.2 million in Q3 2025 to a low of $844000.0 in Q4 2023.
- A 5-year average of $2.7 million and a median of $2.3 million in 2022 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 534.92% — and 2023, when it sank 66.6%.
- Tracing URGN's Operating Leases over 5 years: stood at $2.5 million in 2022, then slumped by 66.6% to $844000.0 in 2023, then soared by 95.85% to $1.7 million in 2024, then jumped by 270.36% to $6.1 million in 2025, then retreated by 7.76% to $5.6 million in 2026.
- The last three Operating Leases figures came in at $5.6 million (Q1 2026), $6.1 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.04 Mn |
| Mar 31, 2026 | 5.65 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | 3.41 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 844,000.00 |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | 2.12 Mn |
| Mar 31, 2023 | 2.37 Mn |
| Dec 31, 2022 | 2.53 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 2.33 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 398,000.00 |
| Sep 30, 2021 | 616,000.00 |